Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Sensitizing pre-clinical neuroendocrine tumor models to radiotherapy
FY 2023-24
Summary
Neuroendocrine tumors (NETs) are cancers that arise throughout the body in specialized cells responsible for making hormones. When these cancers form in the gastrointestinal tract or pancreas, these tumors are known as gastroenteropancreatic NETs (GEP-NETs). Patients diagnosed with GEP-NETs have a survival rate between 4% and 35% due to the lack of screening tests and effective treatment options. While some tumors initially shrink with radiation therapy, the cancer ultimately continues to develop in all patients. As such, there is a pressing need to identify strategies to enhance patient response to radiation. One strategy that has shown promise in pre-clinical studies with other cancer types involves treating cells with radiation and drugs at the same time. The drugs used in these studies either activate or inhibit a cellular process known to be altered in cancer cells called autophagy. Based on this research, in this study we will first examine how autophagy is altered specifically in GEP-NET cancer cells. We will then treat GEP-NET cancer cells with FDA-approved drugs to assess if activating or inhibiting autophagy will change how cells respond to radiation therapy. Drugs that slow the growth of cancer cells when treated with radiation will then be tested in more clinically relevant models that use samples from patients with GEP-NETs. Overall, this study will help to identify new therapeutic options and treatment plans for patients with GEP-NETs, ultimately resulting in better health outcomes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506163
Name
Viola Lauren M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Sensitizing pre-clinical neuroendocrine tumor models to radiotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autophagy; Cancer; Cancer Therapy; Gastroenteropancreatic Neuroendocrine Tumors (Gep-Nets); Neuroendocrine Tumors (Nets); Peptide Receptor Radionuclide Therapy (Prrt)
Abstract
Neuroendocrine tumors (NETs) are cancers that arise throughout the body in specialized cells responsible for making hormones. When these cancers form in the gastrointestinal tract or pancreas, these tumors are known as gastroenteropancreatic NETs (GEP-NETs). Patients diagnosed with GEP-NETs have a survival rate between 4% and 35% due to the lack of screening tests and effective treatment options. While some tumors initially shrink with radiation therapy, the cancer ultimately continues to develop in all patients. As such, there is a pressing need to identify strategies to enhance patient response to radiation. One strategy that has shown promise in pre-clinical studies with other cancer types involves treating cells with radiation and drugs at the same time. The drugs used in these studies either activate or inhibit a cellular process known to be altered in cancer cells called autophagy. Based on this research, in this study we will first examine how autophagy is altered specifically in GEP-NET cancer cells. We will then treat GEP-NET cancer cells with FDA-approved drugs to assess if activating or inhibiting autophagy will change how cells respond to radiation therapy. Drugs that slow the growth of cancer cells when treated with radiation will then be tested in more clinically relevant models that use samples from patients with GEP-NETs. Overall, this study will help to identify new therapeutic options and treatment plans for patients with GEP-NETs, ultimately resulting in better health outcomes.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Viola, Lauren M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~